Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Re-Dian Yang"'
Autor:
Lian-Min Luo, Re-Dian Yang, Jia-Min Wang, Shan-Kun Zhao, Yang-Zhou Liu, Zhi-Guo Zhu, Qian Xiang, Zhi-Gang Zhao
Publikováno v:
Asian Journal of Andrology, Vol 22, Iss 5, Pp 532-538 (2020)
5α-reductase inhibitors (5-ARI) are widely employed for the treatment of benign prostatic hyperplasia. It has been noted that 5-ARI exhibit the potential to attenuate the risk of prostate cancer, but consistent agreement has not been achieved. Moreo
Externí odkaz:
https://doaj.org/article/0547b882e71a4d3388ae27a5a9958383
Autor:
Jiamin Wang, Ermao Li, Qiang Xie, Re-Dian Yang, Zhigang Zhao, Chaofeng Zhang, Shankun Zhao, Zhiguo Zhu, Yangzhou Liu, Lianmin Luo
Publikováno v:
Cancer Management and Research
Objective To assess whether radiotherapy (RT) for prostate cancer (PCa) was a risk factor for secondary bladder cancer (BLCa) through a meta-analysis. Materials and methods The MEDLINE, Embase, and the Cochrane Library were systematically searched fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b7f8f17b4bf10a739f5b3531d52c462
http://europepmc.org/articles/PMC6331076
http://europepmc.org/articles/PMC6331076
Autor:
Yangzhou Liu, Jiamin Wang, Qian Xiang, Zhigang Zhao, Re-Dian Yang, Lianmin Luo, Shankun Zhao, Zhiguo Zhu
Publikováno v:
Asian Journal of Andrology
Asian Journal of Andrology, Vol 22, Iss 5, Pp 532-538 (2020)
Asian Journal of Andrology, Vol 22, Iss 5, Pp 532-538 (2020)
5α-reductase inhibitors (5-ARI) are widely employed for the treatment of benign prostatic hyperplasia. It has been noted that 5-ARI exhibit the potential to attenuate the risk of prostate cancer, but consistent agreement has not been achieved. Moreo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d7944a73d277742fc034743812db6dc
https://pubmed.ncbi.nlm.nih.gov/31710001
https://pubmed.ncbi.nlm.nih.gov/31710001